1. Large cell and small cell neuroendocrine bladder carcinoma: immunohistochemical and outcome study in a single institution.
- Author
-
Alijo Serrano F, Sánchez-Mora N, Angel Arranz J, Hernández C, and Alvarez-Fernández E
- Subjects
- Adult, Aged, Aged, 80 and over, Carcinoma, Neuroendocrine mortality, Carcinoma, Neuroendocrine therapy, Carcinoma, Small Cell, Combined Modality Therapy, Female, Hospitals, University, Humans, Male, Middle Aged, Neoplasm Staging, Prognosis, Spain epidemiology, Survival Rate, Treatment Outcome, Urinary Bladder Neoplasms mortality, Urinary Bladder Neoplasms therapy, Biomarkers, Tumor analysis, Carcinoma, Neuroendocrine chemistry, Carcinoma, Neuroendocrine pathology, Neoplasm Proteins analysis, Urinary Bladder Neoplasms chemistry, Urinary Bladder Neoplasms pathology
- Abstract
We studied 44 cases of small cell bladder carcinoma (SCBC) and 2 cases of large cell neuroendocrine bladder carcinoma (LCNBC) to determine the immunohistochemical profile and biologic behavior. Thyroid transcription factor (TTF)-1, cytokeratin (CK)20, chromogranin A (CgA), synaptophysin, neuron-specific enolase (NSE), and Leu-7 studies were performed. TTF-1+ cases were stained for surfactant protein A (SP-A). The immunohistochemical profile for 44 SCBC cases was as follows: TTF-1+, 11 (25%); CK20+, 3 (7%); CgA+, 13 (30%); synaptophysin+, 22 (50%); NSE+, 35 (80%); and Leu-7+, 30 (68%), and for 2 LCNBC cases was as follows: TTF-1+, 2 (100%); CgA+, (50%); synaptophysin+, 1 (50%); NSE+, 2 (100%); and Leu- 7+, 2 (100%). All cases with TTF-1 expression were negative for SP-A, except 1 case. This case was a mixed SCBC with TTF-1 expression in the urothelial component, which also expressed SP-A. Immunohistochemical markers were not associated with survival. The prognosis of SCBC is relatively better than its pulmonary counterpart. LCNBC seems to be a rarely recognized entity. TTF-1 expression is not limited to small cell lung carcinoma.
- Published
- 2007
- Full Text
- View/download PDF